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Hypertrophic cardiomyopathy (HCM) is a disease of the 
myocardium that is estimated to affect one in 500 
individuals (Marian & Roberts, 2001; Maron, 2002).  
Additionally, it is the most common form of 
cardiovascular disease in the domestic cat (Kittleson et 
al., 1999).  Mutations in the cardiac myosin binding 
protein C (MYBPC3) gene are the most common genetic 
cause of HCM in humans (Richard et al., 2003) and are 
currently the only gene with identified mutations in cats 
(Meurs et al., 2005; Meurs et al., 2007).   The function of 
the protein encoded by the MYBPC3 gene is not well 
understood, but further research into this area will 
hopefully provide more information about the 
manifestation of the disease and will allow for the 
identification of prospective treatments.  With continued 
investigation, more can be learned about normal cardiac 
function, which could be applied in understanding HCM 




Cardiovascular disease is a public health problem that 
affects millions of individuals world-wide.  Cardiomyopathies 
represent a major cause of cardiovascular morbidity and 
death, usually as a result of heart failure, arrhythmias, or 
sudden death during strenuous physical activity (Richard et 
al., 2006; Seidman & Seidman, 2001).  They are defined as 
disease of the myocardium, the thick muscular wall of the 
heart (Seidman & Seidman, 2001).  There are four main 
classifications of cardiomyopathy, but the two most prevalent 
forms are dilated, which results in an increase in cardiac 
chamber volumes, and hypertrophic, which results in an 
increase in ventricular wall thickness (Richard et al., 2006; 
Seidman & Seidman, 2001).  The role of genetics in the 
etiology of these diseases has been the focus of extensive 
research in the medical field for the past fifteen years, which 
has resulted in a fundamental change in conventional 
knowledge surrounding cardiac function and the 
pathogenesis of these disorders.   
Hypertrophic cardiomyopathy (HCM) is a 
myocardial disease that is associated with cardiac 
dysfunction due to asymmetrical thickening of the left 
ventricular wall and myocyte disarray (Richard et al., 2003; 
Richard et al., 2006; Seidman & Seidman, 2001). In humans, 
HCM has an estimated prevalence of one in 500, and it is 
believed to be the most common genetic form of 
cardiovascular disease (Marian & Roberts, 2001; Maron, 
2002).  Additionally, it has been estimated that the disease is 
inherited as a familial disease in at least 60% of cases 
(Marian & Roberts, 2001).  Familial HCM is characterized by 
an autosomal dominant mode of disease inheritance and is 
both genetically and clinically heterogeneous (Charron et al., 
1998; Richard et al., 2003).   
________________________________________________  
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Causative mutations for HCM have been identified 
in thirteen genes encoding sarcomeric proteins (Richard et 
al., 2006), including the ß cardiac myosin heavy chain 
(MYH7), cardiac troponin T (TNNT2), and cardiac myosin 
binding protein C (MYBPC3) genes (Richard et al., 2003).  
Comprehensive studies by Richard et al. (2003) and Van 
Driest et al. (2005) both determined that mutations in 
MYBPC3 were the most common cause of HCM, accounting 
for 42% and 20% of mutations in the respective study 
populations. 
HCM is also commonly observed in veterinary 
medicine and has been identified as the most common form 
of cardiac disease in domestic cats (Kittleson et al., 1999).  
Feline HCM is heritable and has been noted to be present 
more frequently in specific breeds, such as the Maine Coon 
and the Ragdoll (Kittleson et al, 1999; Meurs et al., 2005; 
Meurs et al., 2007).  Clinical and pathological analysis have 
demonstrated that heritable HCM in cats closely resembles 
familial HCM in humans, and it has thus been proposed that 
cats may serve as a natural animal model of the disease 
(Fox et al., 1995; Kittleson et al., 1999).  Recent studies 
have identified causative mutations in the feline MYBPC3 
gene in Maine Coon and Ragdoll colonies with familial HCM.  
This suggests that changes in the cardiac myosin binding 
protein C due to mutations in the MYPBC3 gene may be an 




Hypertrophic Cardiomyopathy has been associated with 
distinctive structural and cellular abnormalities within the 
heart.  As previously mentioned, the principal anatomical 
feature of HCM is left ventricular hypertrophy, which is 
generally asymmetric and often involves the interventricular 
septum (Richard et al., 2003; Richard et al., 2006; Seidman 
& Seidman, 2001).  In humans, left ventricular wall thickness 
is generally less than 12 mm, but can range from 13 mm to 
60 mm in individuals with HCM (Maron, 2002).  As a 
consequence of this abnormal ventricular morphology, the 
volumes of the left ventricular chambers are diminished 
considerably (Seidman & Seidman, 2001).   
At the cellular level, HCM is associated with an 
increase in the size of cardiac muscle cells (myocytes), 
which ultimately causes an increase in cardiac mass 
(Seidman & Seidman, 2001).  In addition, the enlarged, 
irregularly shaped myocytes can result in an overall 
disruption of myocardial cell architecture throughout the 
ventricle, collectively termed myocyte disarray (Seidman & 
Seidman, 2001).  Interstitial fibrosis, in which more cardiac 
fibroblasts and extracellular matrix are present than in the 
healthy heart, is also common and has been associated with 
increased cardiac stiffness (Seidman & Seidman, 2001).  In 
conjunction with the decrease in ventricular volume, this 
alteration in the heart’s anatomy can impair relaxation during 
ventricular diastole, which hinders atrial emptying of the 
blood (Seidman & Seidman, 2001). 
 Within the medical community, HCM is recognized 
as heterogeneous in clinical expression, natural history, and 
prognosis (Maron, 2002; Richard et al., 2006).  Hence, 
clinical manifestations of HCM are very diverse, with some 
affected individuals living a normal life span and 
experiencing no symptoms of the disease.  Others, however, 
will experience dyspnea (difficulty breathing), syncope 
(fainting), angina (chest pain), arrhythmias, life-threatening 
heart failure, and sudden death (Seidman & Seidman, 2001; 
79 
Van Driest et al., 2005; Richard et al., 2006).  Presentation 
of disease phenotype can occur at virtually any age, from 
infancy to greater than 90 years of age (Lever et al., 1989; 
Maron et al., 1982; Maron, 2002; Niimura et al., 2002).  
Clinically, HCM is usually identified through 
echocardiographic examination, but diagnosis of HCM will 
only be made in the absence of any other cardiac or 
systemic disease that could cause similar symptoms (Maron, 
2002; Seidman & Seidman, 2001).  
Clinical genetic testing for HCM is not widely 
available and is complicated by the involvement of numerous 
genes and a diverse array of mutations in the disease 
genotype (Van Driest, 2005).  The best approach to genetic 
testing may be to first target the two genes associated with 
the greatest number of mutations, MYH7 and MYBPC3 
(Richard et al., 2003; Van Driest et al., 2005).  Further 
research into the possibility of gene-specific phenotypes in 
HCM patients may be beneficial prior to beginning 
widespread genetic testing, however, since research thus far 
has produced conflicting reports about whether progression 
of the disease varies depending on which gene carries the 
mutation (Anderson et al., 2004; Charron et al., 1998; 
Richard et al., 2006; Van Driest, 2005).  
 Due to the phonotypical heterogeneity of the 
disease, treatment strategies for HCM should be evaluated 
in terms of specific subgroups within the hypertrophic 
cardiomyopathy clinical spectrum.  For patients at high risk 
of sudden death, the most effective treatment is the 
implantable cardioverter-defibrillator (Maron, 2002).  Drug 
therapies such as ß-blockers, calcium channel blockers, 
antiarrhythmic agents, and diuretics, are generally utilized 
with patients showing signs of progressive heart failure, 
although heart transplantation is sometimes necessary 
(Maron, 2002).  It is important to note, however, that except 
for organ transplant surgery, these treatments do not halt the 
progression of the disease.  Ideally, more effective 
treatments will arise as a result of further investigation into 
the genetic and pathological basis of the disease.  
  
Cardiac Myosin Binding Protein C 
 
Mutations in the gene encoding the sarcomeric protein 
cardiac myosin binding protein C, MYBPC3, are recognized 
as a major cause of hypertrophic cardiomyopathy in humans 
and domestic cats (Kittleson et al., 1999; Meurs et al., 2005; 
Meurs et al., 2007; Richard et al., 2003; Van Driest et al., 
2005).  As a consequence, cMyBP-C has been the focal 
point of extensive research, which has provided valuable 
information about the gene, the resulting protein, and their 
significance in the manifestation of HCM. 
Gene Characteristics 
 MYBPC3 encodes the cardiac isoform of myosin 
binding protein-C, which is found in the A bands of nearly all 
vertebrate striated muscle (Harris et al., 2002; Sadayappan, 
2006).  Unlike the genes for other myosin binding protein-C 
isoforms, however, MYBPC3 is almost exclusively 
expressed in heart muscle (Harris et al., 2002).  The 
MYBPC3 gene is located on chromosome 11p11.2, as was 
initially determined by Gautel et al. (1995) through 
fluorescent in situ hybridization (FISH).  The physical 
mapping of MYBPC3 to this location was one of the first 
indications that it may be associated with hypertrophic 
cardiomyopathy, which had previously been linked to 
mutations in this region (Gautel et al., 1995).  According to 
AceView, the gene covers 21.3 kb on the reverse DNA 
strand.  It contains 34 introns and transcription produces 
nine different mRNA (National Center for Biotechnology 
Information, 2007).  Six of the introns are alternatively 
spliced, while the remaining three are unspliced forms 
(NCBI, 2007).  Interestingly, only six of the nine mRNA 
variants are translated into proteins, suggesting that three of 
the mRNAs are non-coding (NCBI, 2007). 
 
Protein Structure and Function 
Cardiac myosin binding protein C (cMyBP-C) is a member of 
the intracellular immunoglobulin (Ig) superfamily and is 
comprised of Ig and fibronectin type III repeating domains 
labeled C0-C10 (see Figure 1) (Gautel et al., 1995; 
Kulikovskaya, 2007; Sadayappan, 2006).  It contains myosin 
and titin binding sites near the C-terminus and actin binding 
sites at the protein’s N-terminus (Kulikovskaya et al., 2003; 
Winegrad, 1999).  In contrast to the skeletal muscle isoforms 
of myosin binding protein C, cMyBP-C contains an extra Ig 
domain at the N-terminus, a proline rich 28 residue insertion 
within the C5 domain, and three potential phosphorylation 
sites between the C1 and C2 domains (Gautel et al., 1995; 
Oakley et al., 2004; Sadayappan et al., 2006).  These  
phosphorylation sites consist of serine residues that act as 
substrates for differential phosphorylation by the enzymes 
cAMP-dependent PKA, PKC, and Ca
2+
-calmodulin-activated 




Figure 1. Diagram of cardiac myosin binding protein C. Diagram of cMyBP-C structure, indicating domains and sites of interaction with actin, 
myosin, and titin.  Location of the three phosphorylation sites is also shown.  Cardiac specific regions are shaded.  Modified from Kulikovskaya et al., 
2007 & Sarikas et al., 2005. 
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cMyBP-C is localized to the A-region of arcomeric 
thick filaments in the myocardium, where there are believed 
to be three molecules of cMyBP-C approximately every 43 
nm (Granzier, 2006; Harris, 2002; Kulikovskaya, 2007; 
Sadayappan, 2006; Yank, 1998).  cMyBP-C is believed to 
play a role in cardiac regulation and structure, but its specific 
functions are not well understood.   Studies involving 
knockout mice lacking cMyBP-c provided evidence that the 
protein is not required for cardiac sarcomere development; 
however, it is still necessary for normal cardiac function 
since its absence resulted in severe cardiac hypertrophy and 
impaired contractile function (Harris et al., 2002).  This 
supports earlier findings that indicated that cMyBP-C might 
be involved in cardiac contractility (Gautel et al., 1995). 
The functions of cMyBP-C may be regulated by 
Ca
2+
-regulated kinase phosphorylation, which has been 
shown to alter thick filament structure and stability 
(McClellan et al., 2001; Kulikovskaya et al., 2003; 
Kulikovskaya et al., 2007).  Phosphorylation results in a 
more stable thick filament, with well-ordered myosin heads 
and increased resistance to damage when subjected to a 
strong force (Kulikovskaya et al., 2003; Kulikovskaya et al., 
2007).  Additionally, cMyBP-C prevents binding of the N-
terminus to myosin and increases the likelihood that it will 
bind to actin thin filaments (Kulikovskaya et al., 2003; 
Kulikovskaya et al., 2007; Sadayappan et al., 2006).  These 
changes are believed to affect thick filament organization 
and sarcomeric integrity (Sadayappan et al., 2006).  
Interestingly, a study by Sadayappan et al. (2006) indicated 
that in maintaining thick filament organization and structure, 
phosphorylation of cMyBP-C plays a critical role in cardio-
protection. 
 In addition to affecting structure, phosphorylation 
and dephosphorylation of cMyBP-C are suspected to 
regulate cardiac contraction by modulating sensitivity to Ca
2+
 
and ß-adrenergic stimulation (Gautel et al., 1995; 
Kulikovskaya et al., 2003, Kulikovskaya et al., 2007; 
Sadayappan, 2006).  Switching the binding of the N-terminus 
of cMyBP-C between actin and myosin may be another way 
in which phosphorylation and dephosphorylation can 
regulate cardiac contractility (Kulikovskaya et al., 2003).  
This is consistent with the model for muscle contraction, 
which is initiated by entry of calcium into the sarcomere.  
This causes sliding of the thick and thin filaments, which 
contain myosin and actin, respectively (Seidman & Seidman, 
2001).  More research is required, however, to gain a more 
complete understanding of the mechanisms by which 
cMyBP-C may carry out each of these functions, which are 
clearly essential to cardiac stability. 
  
Genetic Mutations and Molecular Changes Associated with 
HCM 
According to Richard et al. (2006), there are approximately 
150 identified mutations in the MYBPC3 gene that cause 
HCM in humans, and they are located along the entire span 
of the gene.  About 70% of the mutations are nonsense 
mutations that lead to premature termination codons, splice 
site mutations, small deletions or insertions, or frameshift 
mutations (Richard et al., 2006).  The remaining mutations 
are believed to be missense mutations, which have an 
amino acid change within the protein sequence (Richard et 
al., 2006).  Frameshift mutations appear to be the most 
common mutations found in individuals with HCM (Richard 
et al., 2003; Sarikas et al., 2005) and are suspected to lead 
to happloinsufficiency.  This could either be due to the 
production of a truncated form of the protein or degradation 
of the mutant mRNA transcript (Richard et al., 2003; Richard 
et al., 2006).  
Studies of gene disruption in model organisms 
have provided valuable insight into the processes by which 
mutations in the MYBPC3 gene can lead to the HCM 
phenotype.  In a 1998 study of a mouse model of HCM, 
researchers created transgenic mice expressing a murine 
isoform of cMyBP-C that lacked both the titin and myosin 
binding domains (Yang et al., 1998).  The mutant protein 
was found to be stable, but was not incorporated efficiently 
into the sarcomere.  In addition, expression of the mutant 
protein lead to decreased levels of normal cMyBP-C, which 
caused sarcomeric disorganization and reduced power 
output within cardiac muscle fibers.  More recently, 
investigation of rat hearts demonstrated that loss of cMyBP-
C makes the thick filament more susceptible to 
fragmentation when exposed to a strong force than intact 
filaments.  Forces such as this may exist in parts of the heart 
during normal contraction, which suggests that lacking 
cMyBP-C can accelerate thick filament degradation 
(Kulikovskaya et al., 2007).   
Scientists’ understanding of the molecular basis 
for HCM was further complicated by a study in which 
truncated proteins resembling those produced by mutations 
identified in HCM patients were expressed in neonatal rat 
cardiomyocytes (Sarikas et al., 2005).  The truncated 
cMyBP-C appeared to be rapidly eliminated by the ubiquitin-
proteasome system for intracellular degradation, rather than 
being incorporated into the sarcomere.  In addition, the 
mutant cMyBP-C was found to impair the ubiquitin-
proteasome system’s ability to degrade other molecules, 
which was hypothesized to be a contributing factor in the 
pathogenesis of HCM (Sarikas et al., 2005).  In conjunction 
with research in humans, these genetic studies indicate that 
the mechanisms by which mutations in MYBPC3 cause 
HCM are very complex, suggesting that further research is 
required to elucidate the multiple factors contributing to the 
manifestation of the disease. 
 
Feline Models of HCM: MYBPC3 Mutations 
In 2005, a research team lead by Dr. Kathryn Meurs 
discovered the first spontaneously occurring mutation 
causing heritable HCM in a non-human species.  The 
mutation was found in a family of Maine Coon cats that had 
been previously diagnosed with the disease.  HCM in this 
colony of cats was shown to closely resemble the human 
form by Kittleson et al. in 1999.  They found that, consistent 
with HCM in humans, these cats presented varying 
phenotypes, from mild to severe (Kittleson et al., 1999).  
These results lead to the proposal that affected cats are a 
valuable, naturally occurring animal model for studying the 
cellular, molecular, and anatomical aspects of HCM and may 
be an important resource for studying possible therapeutic 
treatments of the condition (Kittleson et al., 1999).  
In the study by Meurs et al. (2005), affected Maine 
Coon cats were determined to have a causative mutation in 
exon 3 of the feline ortholog of the MYBPC3 gene.  The 
mutation, a single base pair change of G to C, modified the 
amino acid sequence of the cMyBP-C protein, which was 
predicted to result in an alteration in protein structure.  This 
abnormal conformation may explain the sarcomeric 
disorganization and increased left ventricular wall thickness 
(range = 6-9 mm, normal = 3-5mm) observed in these cats.  
Furthermore, affected cats were found to have decreased 
levels of the cMyBP-C protein in their myocardium in 
comparison to control cats (p < 0.001).  This may indicate 
that the mutated proteins are degraded due to their instability 
and their inability to integrate into the sarcomere, supporting 
the previously mentioned findings by Sarikas et al. (2005).   
More recently, a second mutation in the feline 
MYBPC3 gene was identified in a similar population of 
Ragdoll cats with HCM (Meurs et al., 2007).  The mutation 
caused similar phenotypes, but was in a different domain 
than the Maine Coon mutation.  This suggests that the two 
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mutations were independent and not the result of a common 
founder.  The mutations resulted in a change from arginine 
to tryptophan in the protein’s amino acid sequence due to a 
single base pair change from C to T in codon 820, yielding 
an abnormal protein product.  These discoveries in feline 
models of HCM provided more evidence for the importance 
of the MYBPC3 gene in cardiac structure and function and 
illustrate that it is a key component of hypertrophic 




The study of cardiac myosin binding protein C and 
associated mutations in the MYBPC3 gene has provided a 
more comprehensive understanding of hypertrophic 
cardiomyopathy in humans and domestic felines.  Our 
knowledge about this disease as a whole, however, remains 
quite limited, necessitating investment in further research.  
Additional research should focus on identifying the complete 
spectrum of polymorphisms in the MYBPC3 gene that do not 
cause HCM for genetic comparison with mutations in these 
allelic variants.  Elucidating the specific functions of cMyBP-
C is also fundamental to the appreciation of the molecular 
basis for HCM.  Furthermore, continued study of the 
naturally occurring animal model for the disease, the 
domestic cat, may also prove essential to gaining a complete 
understanding of disease pathogenesis and the 
development of prospective treatments. Finally, with 
continued research, more knowledge can be gained about 
normal cardiac function. This, in turn, could be applied to 
understanding cardiovascular disease to develop alternative 
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